CA996548A - .alpha.-SULFOBENZYLPENICILLIN SALT - Google Patents

.alpha.-SULFOBENZYLPENICILLIN SALT

Info

Publication number
CA996548A
CA996548A CA175,329A CA175329A CA996548A CA 996548 A CA996548 A CA 996548A CA 175329 A CA175329 A CA 175329A CA 996548 A CA996548 A CA 996548A
Authority
CA
Canada
Prior art keywords
sulfobenzylpenicillin
alpha
salt
sulfobenzylpenicillin salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA175,329A
Other languages
English (en)
Other versions
CA175329S (en
Inventor
Tsugio Shimamoto
Hiroaki Nomura
Masahiko Fujita
Hiroaki Okada
Hiroshi Fujisawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of CA996548A publication Critical patent/CA996548A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA175,329A 1972-07-01 1973-06-29 .alpha.-SULFOBENZYLPENICILLIN SALT Expired CA996548A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6630172A JPS5512435B2 (cg-RX-API-DMAC7.html) 1972-07-01 1972-07-01

Publications (1)

Publication Number Publication Date
CA996548A true CA996548A (en) 1976-09-07

Family

ID=13311838

Family Applications (1)

Application Number Title Priority Date Filing Date
CA175,329A Expired CA996548A (en) 1972-07-01 1973-06-29 .alpha.-SULFOBENZYLPENICILLIN SALT

Country Status (15)

Country Link
US (1) US3925357A (cg-RX-API-DMAC7.html)
JP (1) JPS5512435B2 (cg-RX-API-DMAC7.html)
AT (1) AT325206B (cg-RX-API-DMAC7.html)
AU (1) AU469986B2 (cg-RX-API-DMAC7.html)
BE (1) BE801588A (cg-RX-API-DMAC7.html)
CA (1) CA996548A (cg-RX-API-DMAC7.html)
CH (1) CH573435A5 (cg-RX-API-DMAC7.html)
CS (1) CS168036B2 (cg-RX-API-DMAC7.html)
DE (1) DE2332840A1 (cg-RX-API-DMAC7.html)
FR (1) FR2190414B1 (cg-RX-API-DMAC7.html)
GB (1) GB1386566A (cg-RX-API-DMAC7.html)
HU (1) HU166029B (cg-RX-API-DMAC7.html)
NL (1) NL7308048A (cg-RX-API-DMAC7.html)
PL (1) PL92969B1 (cg-RX-API-DMAC7.html)
SE (1) SE402916B (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522148U (cg-RX-API-DMAC7.html) * 1978-07-29 1980-02-13
DK1757606T3 (da) * 2001-02-24 2009-09-07 Boehringer Ingelheim Pharma Anvendelse af xanthinderivater som l gemidler samt fremgangsm de til deres fremstilling
US20030171424A1 (en) * 2002-03-07 2003-09-11 Lin Ai J. Intravenous formulation of artelinic acid for treatment of severe and complicated malaria
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
JP5323684B2 (ja) * 2006-05-04 2013-10-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 多形体
AU2008290582B2 (en) * 2007-08-17 2014-08-14 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
EP2326326B1 (en) * 2008-08-15 2019-10-09 Boehringer Ingelheim International GmbH Dpp-4 inhibitors for use for the treatment of wound healing in diabetic patients
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
TWI508965B (zh) 2008-12-23 2015-11-21 Boehringer Ingelheim Int 有機化合物的鹽形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
KR20190071840A (ko) 2009-11-27 2019-06-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
MX366325B (es) 2010-05-05 2019-07-05 Boehringer Ingelheim Int Terapia de combinacion.
CA2803504C (en) 2010-06-24 2022-08-30 Boehringer Ingelheim International Gmbh A combination for diabetes therapy comprising linagliptin and a long-acting insulin
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
KR101985384B1 (ko) 2011-07-15 2019-06-03 베링거 인겔하임 인터내셔날 게엠베하 치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1026793A (fr) * 1949-08-02 1953-05-04 American Cyanamid Co Procédé de préparation de sels de pénicilline
NL6803062A (cg-RX-API-DMAC7.html) * 1967-03-10 1968-09-11
US3557094A (en) * 1968-01-05 1971-01-19 Pfizer & Co C Substituted alkyl esters of alpha-carboxy aryl penicillins
AT290728B (de) * 1968-09-28 1971-05-15 Takeda Chemical Industries Ltd Verfahren zur herstellung neuer penicilline

Also Published As

Publication number Publication date
JPS4925121A (cg-RX-API-DMAC7.html) 1974-03-06
DE2332840A1 (de) 1974-01-17
FR2190414B1 (cg-RX-API-DMAC7.html) 1976-07-02
CH573435A5 (cg-RX-API-DMAC7.html) 1976-03-15
CS168036B2 (cg-RX-API-DMAC7.html) 1976-05-28
FR2190414A1 (cg-RX-API-DMAC7.html) 1974-02-01
AU5760073A (en) 1975-01-09
JPS5512435B2 (cg-RX-API-DMAC7.html) 1980-04-02
PL92969B1 (cg-RX-API-DMAC7.html) 1977-04-30
SE402916B (sv) 1978-07-24
AU469986B2 (en) 1976-02-26
AT325206B (de) 1975-10-10
BE801588A (fr) 1973-12-28
GB1386566A (en) 1975-03-12
NL7308048A (cg-RX-API-DMAC7.html) 1974-01-03
US3925357A (en) 1975-12-09
HU166029B (cg-RX-API-DMAC7.html) 1974-12-28

Similar Documents

Publication Publication Date Title
CA996548A (en) .alpha.-SULFOBENZYLPENICILLIN SALT
AU462348B2 (en) Saf-t-jet
AU467469B2 (en) Trifluoromethylmercaptoacetamindocephalosphorins
AU454372B2 (en) Childsafe actuator-overcap
CA978946A (en) .alpha.-ARYL-4-SUBSTITUTED PIPERIDINOALKANOL DERIVATIVES
AU469305B2 (en) Deipenylyl-alkanoylaminopyridine
CA960666A (en) 1-aminomethyl-2,2-diaryl-cyclo-propanecarboxamides
CA999293A (en) .alpha.-AMINO-P-HYDROXYPHENYLACETAMIDOCEPHALOSPORINS
AU475339B2 (en) S-substituted-2-thiodenosines
AU5128473A (en) Napnthopyrans
AU470359B2 (en) Sulphamoylphenyl-imidazolidinones
AU468159B2 (en) 5-aroyl-furans
CA1013742A (en) Azabenzo-1,5-diazepines
AU467008B2 (en) d, d-DIARYLIMIDAZOLE-2-METHANOLS
AU473297B2 (en) Indolylimidoylheterocyclics
AU467526B2 (en) Pyronorifamycins
AU468599B2 (en) 15-oxasteroids
AU472554B2 (en) Isothocyanobenzoxazoles
CA907632A (en) .alpha.-HALO-PHENYLACETAMIDES
CA904318A (en) .alpha.-POLYHYDROXYPHENYL-2-PIPER-IDINEMETHANOLS
CA900985A (en) .alpha.-CARBOLINES
CA900984A (en) .alpha.-CARBOLINES
CA902108A (en) .alpha.-PROPARGYLAMINOPROPIOPHENONE DERIVATIVE
CA902041A (en) 6-substituted-13-polycarbonalkyl-18,19-dinorpregn-4-en-3-ones
AU477938B2 (en) 1-aminomethyl-2, 2-diarylcyclopropane-carboxamide